University of Iowa Hospitals and Clinics

Clinical Trial Details

Short Title
Official Title
Study for Symptomatic Patients With Pulmonary Arterial Hypertension

COMPASS 2: Effects of Combination of Bosentan and Sildenafil Versus Sildenafil Monotherapy on Morbidity and Mortality in Symptomatic Patients With Pulmonary Arterial Hypertension - A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group, Prospective, Event Driven Phase IV Study

This study will investigate the effects of the combination of bosentan and sildenafil. Patients with symptomatic PAH treated with a stable dose of sildenafil equal to or greater tha 20 mg t.i.d. for at least 12 weeks will be randomized to placebo or bosentan 125 mg b.i.d. All randomized patients will be treated with study drug until the predefined target number of morbidity/mortality events is reached.


Please refer to identifier NCT00303459 for more information

Start Date
April 1, 2006
End Date
September 1, 2014
Gender Preference
Age Group
18 - 99 years
Principal Investigator
Sif Hansdottir, MD
Contact Info

Pulmonary Hypertension Program

Page Scovel, RN

phone:  319-356-1028

Fax:  319-356-7087


Heart ; High blood pressure in lungs ; PAH ; PH ; Pulmonary arterial hypertension ; Pulmonary diseases ; Pulmonary hypertension ;

We welcome your feedback! Please help us improve your experience on our website by completing a brief survey.